News

STAT2h
Pharmalittle: We’re reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...
STAT2h
FDA approves blockbuster Dupixent for chronic hives
The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...
Zacks Investment Research on MSN2h
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...
BioSpace2h
Following Rejection, FDA Okays Sanofi/Regeneron’s Dupixent for Chronic Hives
Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...
PharmExec5h
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...
Sarajevo Times1d
Chinese Tariffs On U.S. Imports Could Complicate The Supply Of Essential Medicines
China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...
Dividend, Stock Split Next Week: Muthoot, Sanofi, Huhtamaki Among 5 to Watch – Check Record Date
Investors need to pay attention to important dates of the Stock split and record date to remain eligible and make necessary ...
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...
BioPharma Dive2d
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...
The American Journal of Managed Care2d
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...
Fierce Pharma3d
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition
On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...
Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU
Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...